April 14, 2021-April 15, 2021 Identifying COAs for Use in Rare Disease Treatment Trials Presented at the PRO Consortium 2021 Workshop, held virtually April 14-15, 2021:
April 7, 2021 Development of a regulatory-ready clinical trial simulation tool for Duchenne muscular dystrophy Abstract WMS 2020
April 7, 2021 Development of a regulatory-ready clinical trial simulation tool for Duchenne muscular dystrophy poster WMS 2020
April 7, 2021 Development of Clinical Trial Simulation Tool for Duchenne Muscular Dystrophy Through the Duchenne Regulatory Science Abstract WMS 2019
April 7, 2021 Development of Clinical Trial Simulation Tool for Duchenne Muscular Dystrophy Through the Duchenne Regulatory Science Poster WMS 2019
A metadata-driven tool to determine the robustness of digital health technologies assessments for Parkinson’s Disease leveraging the voice of the patient – Sakshi Sardar, et al. Abstract # 1314
Metadata standards to support deployment of Digital Health Technologies in Clinical Trials in Parkinson’s Disease – Derek Hill, et al. Abstract # 1289
Identifying and Controlling Variability in Digital Health Measures in Parkinson’s Disease Clinical Trials – George Roussos, et al. Abstract # 342
Data Driven Paths to Advancing Precision Medicine Strategies for Parkinson’s Disease: Critical Path for Parkinson’s Consortium – Martijn Müller, et al. Abstract # 341
The Development of a Parkinson’s Disease Biomarker Inventory Dashboard – Michael Pauley, et al. Abstract # 308
